BriaCell Therapeutics Corp.

BCTX | NASDAQ

Price Alert Chart Builder DCF Calculator

-$0.15 (-3.61%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.61%

(1D)

Rating

Updated: Aug 27, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $34.78M

1D Range

3.96 4.37

52W Range

2.60 14.68

Valuation (TTM)

PE -0.30

PB 1.54

EV/EBITDA -0.43

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target N/A

Cash Flow

FCF Yield -93.9%

SBC Adj. FCF Yield -96.7%

SBC Impact -3.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 12.2% | 18.6%

FCF 3Y | 5Y 10.7% | -19.0%

Returns

ROA -113.2%

ROE -147.9%

ROIC -136.3%

Financial Health

Net Cash

$22.8M

Current Ratio 7.07

Interest Coverage -1,080.17

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is ...

Sector Healthcare

Industry Biotechnology

Employees 16

IPO Date Mar 13, 2012

Website www.briacell.com

Fiscal Year August - July

Full Company Profile

Latest News

No news articles available yet.